Dean F. Bajorin, MD, of Memorial Sloan Kettering Cancer Center, summarizes a panel discussion on this important topic.
Fred Saad, MD, of the University of Montreal, summarizes in French his session on the latest treatment developments in prostate cancer, including the role of chemotherapy in hormone-sensitive disease.
Christopher Brian Allard, MD, of Brigham & Women's Hospital, reports on results of the Physicians’ Health Study, which showed that regular aspirin use decreased the risk of lethal prostate cancer in a cohort of American doctors (Abstract 306).
Fred Saad, MD, of the University of Montreal, summarizes his session on the latest treatment developments in prostate cancer, including the role of chemotherapy in hormone-sensitive disease. To see the French language version of this video, click here.
David P. Dearnaley, MD, of The Royal Marsden NHS Foundation Trust, discusses the comparison, in this study, of hypofractionated high-dose IMRT schedules for prostate cancer (Abstract 2).
Matthew Smith, MD, PhD, of the Massachusetts General Hospital Cancer Center, discusses the best use of approved therapies for tumors that have spread to the bone.
